NCT02019147

Brief Summary

Despite recent advances in the care of mothers and newborn infants, many infants (approximately 20 per 1000 live births) continue to need resuscitation at birth. A proportion of these infants will have sustained significant injury through interruption of their blood and oxygen supply prior to delivery (perinatal asphyxia). In 2-3 babies per 1000 this will lead to brain swelling and the risk of long term brain injury called neonatal hypoxic-ischaemic encephalopathy (HIE). HIE remains a cause of neonatal death and long term disability. Early and accurate prediction of outcome would allow us to intervene during the window of the first 6 hours following birth, prior to secondary reperfusion and secondary brain injury. Estimating severity of injury can be difficult in newborn infants. Condition at birth does not predict neonatal, or longer term outcome. Biomarkers which could be measured at the time of birth and analysed at the bedside would offer these infants the best chance of timely and effective intervention. Through the BIHIVE study we have identified a number of predictive biomarkers in hypoxic-ischaemic encephalopathy. These markers are present in umbilical cord blood and have been identified through proteomic and metabolomic analysis of a stored biobank of samples from a recruited cohort of infants with perinatal asphyxia and hypoxic-ischaemic encephalopathy. We now wish to validate these biomarkers in an additional cohort, and will continue to explore new biomarkers in our stored biobank of umbilical cord samples. In addition we wish to assess our ability to predict neurodevelopmental and behavioural outcome in these infants. In this way we will determine the most robust biochemical and clinical markers for the prediction of early and medium term outcome in HIE. This study will establish the evidence base and validation of these biomarkers to the point where they can be developed into a bedside diagnostic algorithm which can be used in the labour ward to immediately identify those infants at risk of HIE in time to prevent secondary damage.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2012

Longer than P75 for all trials

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

November 6, 2013

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 24, 2013

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

July 6, 2018

Status Verified

July 1, 2018

Enrollment Period

5.4 years

First QC Date

November 6, 2013

Last Update Submit

July 4, 2018

Conditions

Keywords

HIEBiomarker

Outcome Measures

Primary Outcomes (1)

  • EEG confirmed hypoxic-ischaemic brain injury in the first 72 hours of life

    Clinical examination using the Thompson Encephalopathy score and visual interpretation of multichannel EEG

    24 hours

Secondary Outcomes (1)

  • Neurodevelopmental outcome at 2 years of age assessed using BSID III

    18-24 months

Study Arms (2)

Term Hypoxic Ischaemic Encephalopathy

Term Hypoxic Ischaemic Encephalopathy (HIE)

Healthy Term Neonates

Controls

Eligibility Criteria

AgeUp to 1 Hour
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Term Neonates born in hospital

You may qualify if:

  • Term infants defined at greater than 36 weeks gestation
  • All infants with one or more of the following clinical markers of HIE:
  • Apgar score less than or equal to 6 at 5 minutes pH \< 7.1 on cord blood, Requiring intubation or CPR at birth -

You may not qualify if:

  • Outborn babies Less than 36 weeks gestation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Cork University Maternity Hospital

Cork, 00000, Ireland

Location

Karolinska University Hospital

Stockholm, Sweden

Location

Related Publications (17)

  • Conway JM, Walsh BH, Boylan GB, Murray DM. Mild hypoxic ischaemic encephalopathy and long term neurodevelopmental outcome - A systematic review. Early Hum Dev. 2018 May;120:80-87. doi: 10.1016/j.earlhumdev.2018.02.007. Epub 2018 Feb 26.

    PMID: 29496329BACKGROUND
  • O'Connor CM, Ryan CA, Boylan GB, Murray DM. The ability of early serial developmental assessment to predict outcome at 5years following neonatal hypoxic-ischaemic encephalopathy. Early Hum Dev. 2017 Jul;110:1-8. doi: 10.1016/j.earlhumdev.2017.04.006. Epub 2017 Apr 21.

    PMID: 28433953BACKGROUND
  • Murray DM, O'Connor CM, Ryan CA, Korotchikova I, Boylan GB. Early EEG Grade and Outcome at 5 Years After Mild Neonatal Hypoxic Ischemic Encephalopathy. Pediatrics. 2016 Oct;138(4):e20160659. doi: 10.1542/peds.2016-0659. Epub 2016 Sep 20.

    PMID: 27650049BACKGROUND
  • Denihan NM, Boylan GB, Murray DM. Metabolomic profiling in perinatal asphyxia: a promising new field. Biomed Res Int. 2015;2015:254076. doi: 10.1155/2015/254076. Epub 2015 Jan 31.

    PMID: 25802843BACKGROUND
  • Ahearne CE, Boylan GB, Murray DM. Short and long term prognosis in perinatal asphyxia: An update. World J Clin Pediatr. 2016 Feb 8;5(1):67-74. doi: 10.5409/wjcp.v5.i1.67. eCollection 2016 Feb 8.

    PMID: 26862504BACKGROUND
  • Walsh BH, Broadhurst DI, Mandal R, Wishart DS, Boylan GB, Kenny LC, Murray DM. The metabolomic profile of umbilical cord blood in neonatal hypoxic ischaemic encephalopathy. PLoS One. 2012;7(12):e50520. doi: 10.1371/journal.pone.0050520. Epub 2012 Dec 5.

  • Walsh BH, Boylan GB, Dempsey EM, Murray DM. Association of nucleated red blood cells and severity of encephalopathy in normothermic and hypothermic infants. Acta Paediatr. 2013 Feb;102(2):e64-7. doi: 10.1111/apa.12086. Epub 2012 Dec 7.

  • Denihan NM, Kirwan JA, Walsh BH, Dunn WB, Broadhurst DI, Boylan GB, Murray DM. Untargeted metabolomic analysis and pathway discovery in perinatal asphyxia and hypoxic-ischaemic encephalopathy. J Cereb Blood Flow Metab. 2019 Jan;39(1):147-162. doi: 10.1177/0271678X17726502. Epub 2017 Aug 25.

  • Ahearne CE, Chang RY, Walsh BH, Boylan GB, Murray DM. Cord Blood IL-16 Is Associated with 3-Year Neurodevelopmental Outcomes in Perinatal Asphyxia and Hypoxic-Ischaemic Encephalopathy. Dev Neurosci. 2017;39(1-4):59-65. doi: 10.1159/000471508. Epub 2017 May 11.

  • Looney AM, Ahearne CE, Hallberg B, Boylan GB, Murray DM. Downstream mRNA Target Analysis in Neonatal Hypoxic-Ischaemic Encephalopathy Identifies Novel Marker of Severe Injury: a Proof of Concept Paper. Mol Neurobiol. 2017 Dec;54(10):8420-8428. doi: 10.1007/s12035-016-0330-4. Epub 2016 Dec 12.

  • Ahearne CE, Denihan NM, Walsh BH, Reinke SN, Kenny LC, Boylan GB, Broadhurst DI, Murray DM. Early Cord Metabolite Index and Outcome in Perinatal Asphyxia and Hypoxic-Ischaemic Encephalopathy. Neonatology. 2016;110(4):296-302. doi: 10.1159/000446556. Epub 2016 Aug 3.

  • Looney AM, Ahearne C, Boylan GB, Murray DM. Glial Fibrillary Acidic Protein Is Not an Early Marker of Injury in Perinatal Asphyxia and Hypoxic-Ischemic Encephalopathy. Front Neurol. 2015 Dec 21;6:264. doi: 10.3389/fneur.2015.00264. eCollection 2015.

  • Looney AM, Walsh BH, Moloney G, Grenham S, Fagan A, O'Keeffe GW, Clarke G, Cryan JF, Dinan TG, Boylan GB, Murray DM. Downregulation of Umbilical Cord Blood Levels of miR-374a in Neonatal Hypoxic Ischemic Encephalopathy. J Pediatr. 2015 Aug;167(2):269-73.e2. doi: 10.1016/j.jpeds.2015.04.060. Epub 2015 May 19.

  • Denihan NM, Walsh BH, Reinke SN, Sykes BD, Mandal R, Wishart DS, Broadhurst DI, Boylan GB, Murray DM. The effect of haemolysis on the metabolomic profile of umbilical cord blood. Clin Biochem. 2015 May;48(7-8):534-7. doi: 10.1016/j.clinbiochem.2015.02.004. Epub 2015 Feb 16.

  • Reinke SN, Walsh BH, Boylan GB, Sykes BD, Kenny LC, Murray DM, Broadhurst DI. 1H NMR derived metabolomic profile of neonatal asphyxia in umbilical cord serum: implications for hypoxic ischemic encephalopathy. J Proteome Res. 2013 Sep 6;12(9):4230-9. doi: 10.1021/pr400617m. Epub 2013 Aug 21.

  • Denihan NM, Looney A, Boylan GB, Walsh BH, Murray DM. Normative levels of Interleukin 16 in umbilical cord blood. Clin Biochem. 2013 Dec;46(18):1857-9. doi: 10.1016/j.clinbiochem.2013.07.012. Epub 2013 Jul 24.

  • Walsh BH, Boylan GB, Livingstone V, Kenny LC, Dempsey EM, Murray DM. Cord blood proteins and multichannel-electroencephalography in hypoxic-ischemic encephalopathy. Pediatr Crit Care Med. 2013 Jul;14(6):621-30. doi: 10.1097/PCC.0b013e318291793f.

Biospecimen

Retention: SAMPLES WITH DNA

Umbilical cord blood

MeSH Terms

Conditions

Hypoxia-Ischemia, BrainAsphyxia

Condition Hierarchy (Ancestors)

Brain IschemiaCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypoxia, BrainVascular DiseasesCardiovascular DiseasesHypoxiaSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsDeathPathologic ProcessesWounds and Injuries

Study Officials

  • Deirdre Murray, MD

    University College Cork, Ireland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Lecturer, Consultant Paediatrician

Study Record Dates

First Submitted

November 6, 2013

First Posted

December 24, 2013

Study Start

March 1, 2012

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

July 6, 2018

Record last verified: 2018-07

Locations